Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02557321
Registration number
NCT02557321
Ethics application status
Date submitted
20/09/2015
Date registered
23/09/2015
Date last updated
24/03/2022
Titles & IDs
Public title
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
Query!
Scientific title
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Query!
Secondary ID [1]
0
0
PV-10-MM-1201
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Melanoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - PV-10
Treatment: Drugs - Pembrolizumab
Experimental: Phase 1b - PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
Experimental: Phase 2 (Arm 1) - PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
Active Comparator: Phase 2 (Arm 2) - Pembrolizumab (2 mg/kg every 3 weeks)
Treatment: Drugs: PV-10
PV-10 will be administered by intralesional injection every 3 weeks at Day 1 (Week 1), Week 4, Week 7, Week 10 and Week 13
Treatment: Drugs: Pembrolizumab
Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Safety and tolerability of the combination regimen assessed by adverse events (AEs)
Query!
Assessment method [1]
0
0
Phase 1b: Safety and tolerability of the combination regimen will be assessed by monitoring the frequency, duration, severity and attribution of adverse events (AEs) and toxicities requiring discontinuation of study treatment, and evaluating changes in laboratory values and vital signs
Query!
Timepoint [1]
0
0
Start of treatment until 4 weeks after final administration of PV-10
Query!
Primary outcome [2]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [2]
0
0
Phase 2: Response evaluated by blinded independent review committee assessment per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1
Query!
Timepoint [2]
0
0
Up to 24 months from initiation of study treatment
Query!
Secondary outcome [1]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [1]
0
0
Phase 1b: Response evaluated per RECIST 1.1
Query!
Timepoint [1]
0
0
Up to 24 months from initiation of study treatment
Query!
Secondary outcome [2]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [2]
0
0
Phase 1b and 2: Response evaluated per RECIST 1.1
Query!
Timepoint [2]
0
0
Up to 24 months from initiation of study treatment
Query!
Secondary outcome [3]
0
0
Change in immune biomarkers
Query!
Assessment method [3]
0
0
Phase 1b: Peripheral Blood Mononuclear Cells (PBMCs) assessed vs. baseline values for changes in T cell populations
Query!
Timepoint [3]
0
0
Up to 28 weeks from initiation of study treatment
Query!
Secondary outcome [4]
0
0
Overall Survival (OS)
Query!
Assessment method [4]
0
0
Phase 1b and 2
Query!
Timepoint [4]
0
0
24 months from initiation of study treatment for last subject randomized
Query!
Secondary outcome [5]
0
0
Safety and tolerability of the combination regimen assessed by adverse events (AEs)
Query!
Assessment method [5]
0
0
Phase 2: Safety and tolerability of the combination regimen will be assessed by monitoring the frequency, duration, severity and attribution of adverse events (AEs) and toxicities requiring discontinuation of study treatment, and evaluating changes in laboratory values and vital signs
Query!
Timepoint [5]
0
0
Start of treatment until 4 weeks after final administration of PV-10
Query!
Eligibility
Key inclusion criteria
1. Age 18 years or older, male or female.
2. Histologically or cytologically confirmed diagnosis of melanoma.
3. Stage IV or Stage III (unresectable, in-transit or satellite) melanoma.
4. At least 1 Injectable Lesion (i.e., cutaneous, subcutaneous, soft tissue, superficial
nodal or palpable nodal lesion with longest diameter at least 5 mm that is suitable
for injection with PV-10).
5. A minimum of 1 measurable Target Lesion that can be accurately measured by calipers,
computed tomography (CT) or magnetic resonance imaging (MRI) consisting of at least
one of the following:
- at least one cutaneous lesion (each lesion = 10 mm longest diameteror up to 5
lesions in aggregate having a sum of longest diameters = 10 mm); and/or
- at least one subcutaneous or soft tissue lesion (each lesion = 10 mm in longest
diameter by CT or MRI); and/or
- at least one nodal lesion (each lesion = 15 mm in short axis diameter by CT or
MRI); and/or
- at least one visceral lesion (each lesion = 10 mm in longest diameter by CT or
MRI).
6. Performance Status: Eastern Cooperative Oncology Group (ECOG) 0-1.
7. Clinical Laboratories:
- absolute neutrophil count (ANC) = 1.5 x 109/L and platelet count =100 x 109/L
- estimated creatinine clearance (CrCl, by Cockcroft-Gault formula) or estimated
glomerular filtration rate (eGFR) = 30 mL/min/1.73 m2
- total bilirubin = 3 times the upper limit of normal (ULN)
- aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase
(ALP) = 5 times the upper limit of normal (ULN)
8. Thyroid function abnormality = Common Toxicity Criteria for Adverse Effects (CTCAE)
Grade 2.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Untreated or clinically active melanoma brain metastases.
- Subjects with = 3 brain metastases and each = 1 cm size that were treated with
either surgical resection and/or radiation therapy are eligible for study
participation provided (a) there is no evidence of progressive central nervous
system (CNS) disease on brain imaging at least 30 days after definitive treatment
and (b) the subject is not taking prednisone at >10 mg or equivalent daily.
- Subjects with > 1 cm or > 3 in number treated brain metastases are eligible for
study participation provided (a) there is no evidence of progressive CNS disease
on brain imaging at least 90 days after treatment with surgery and/or radiation
therapy and (b) if the subject is not taking prednisone at >10 mg or equivalent
daily.
2. Prior treatment with PV-10 or any checkpoint inhibitor; however, subjects (a) who have
failed to achieve a complete or partial response within 24 weeks following initiation
of checkpoint inhibition or (b) who progressed after more than 12 weeks of checkpoint
inhibition are eligible for study participation in the Phase 1b Expansion Cohort 1
without washout period for checkpoint inhibition.
3. Other prior cancer therapy or anti-cancer vaccine within the lesser of 4 weeks or 5
half-lives before initial study treatment.
4. Known sensitivity to any of the products or components to be administered during
dosing.
5. Concurrent or Intercurrent Illness:
- History or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis,
vasculitis, or other systemic autoimmune disease.
- Evidence of clinically significant immunosuppression.
- Impaired wound healing or other extremity complications due to severe or
uncontrolled diabetes mellitus in subjects whose Injectable Lesions are located
in an extremity.
- Severe peripheral vascular disease (i.e., severe claudication [pain occurring
after less than 200 meters of walking], rest pain, ischemic ulceration or
gangrene) in subjects whose Injectable Lesions are located in an extremity.
- Significant concurrent or intercurrent illness, psychiatric disorders, or alcohol
or chemical dependence that would, in the opinion of the Investigator, compromise
the subject's safety or compliance or interfere with interpretation of study
results.
- Uncontrolled thyroid disease or cystic fibrosis.
- Clinically significant acute or unstable cardiovascular, cerebrovascular
(stroke), renal, gastrointestinal, pulmonary, immunological, endocrine, or
central nervous system disorders.
- Malignancy other than melanoma within 2 years of enrollment except for:
adequately treated (i.e., with curative intent) basal or squamous cell carcinoma,
in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in
situ prostate cancer, or limited stage bladder cancer.
6. Pregnancy:
- Female subjects who are pregnant or lactating.
- Female subjects who have positive serum pregnancy test taken within 14 days of
initiation of study treatment.
- Female subjects of childbearing potential (defined as having a menstrual cycle
within the past 12 months and not having had a surgical procedure to accomplish
sterilization) who are not using highly effective contraception (e.g., oral
contraceptives, intrauterine devices, double barrier methods such as condoms and
diaphragms, abstinence or equivalent measures).
- Male subjects who are unwilling to use acceptable method of effective
contraception.
7. Subjects unable to comprehend and give informed consent are excluded.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/11/2024
Query!
Actual
Query!
Sample size
Target
192
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
0
0
Princess Alexandra Hospital - Brisbane
Query!
Recruitment postcode(s) [1]
0
0
4102 - Brisbane
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
New Hampshire
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Oregon
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Pennsylvania
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Texas
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Provectus Biopharmaceuticals, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is an international multicenter, open-label, sequential phase study of intralesional
(IL) PV-10 in combination with immune checkpoint inhibition. Metastatic melanoma patients
(Stage IV or Stage III unresectable, in-transit or satellite disease) with at least one
injectable lesion who are candidates for pembrolizumab (both treatment naïve patients and
treatment refractory patients who have failed to achieve a complete or partial response to or
previously progressed on one or more checkpoint inhibitor) will be eligible for study
participation. In the Phase 1b portion of the study, all participants will receive the
combination of IL PV-10 and pembrolizumab (i.e., PV-10 + standard of care). In the subsequent
Phase 2 portion of the study participants will be randomized 1:1 to receive either the
combination of IL PV-10 and pembrolizumab or pembrolizumab alone (i.e., PV-10 + standard of
care vs. standard of care).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02557321
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Eric Wachter, Ph.D.
Query!
Address
0
0
Provectus Pharmaceuticals, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Eric Wachter, Ph.D.
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
865-769-4011
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02557321
Download to PDF